secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indaptus Therapeutics, Inc. (INDP)
CIK:        0001857044
Form:       8-K
Filed at:   2026-04-03T23:59:59+00:00
Accession:  0001493152-26-015079
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Indaptus Therapeutics appoints Yu Ding as CFO, Qinglai Lu to board; CFO Nir Sassi resigns
--------------------------------------------------------------------------------

- Nir Sassi resigned as CFO effective April 1, 2026; resignation not due to disagreement.
- Yu Ding appointed CFO effective April 1, 2026; brings experience from Grand Auto Service and Hong Kong listed firms.
- Qinglai Lu appointed to Board of Directors effective April 8, 2026; deemed independent.
- Qinglai Lu also appointed to Audit Committee along with Jerome Jabbour; Matthew McMurdo resigned from Audit Committee.
- New CFO Yu Ding has over 20 years experience in financial planning, capital management.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1857044/000149315226015079/0001493152-26-015079-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1857044/000149315226015079/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-015079

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer